Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

Exclusion Criteria

• •Essential hypertension based on a Diastolic Blood Pressure (DBP) ≥ 110mmHg and Systolic Blood Pressure (SBP) ≥ 180 mmHg;
• •Secondary hypertension;
• •Participants with Body Mass Index (BMI) \> 35 Kg/m2;
• •Non-controlled types 1 and 2 diabetes mellitus (HbA1 \> 8,5%);
• •Myocardial infarction, coronary surgery or coronary angioplasty with or without stent placement, in the last 6 months;
• •Unstable angina;
• •Participants with coronary heart disease taking beta-blockers;
• •Clinically manifest heart failure;
• •History of cardiac arrhythmia;
• •Moderate and severe heart valve disease;
• •Stroke or transient ischemic attack in the last 6 months;
• •Chronic disease of any nature that contraindicates the participant's participation according to the investigator's judgment, in particular renal failure with glomerular filtration rate \< 45 ml/min, serum potassium levels ≥ 5,5 mEq/L or ≤ 3,5 mEq/L, hepatopathies, or SGOT, SGPT or bilirubin levels 3 times above the normal upper limit, and blood dyscrasias;
• •Known allergies or contraindication to the use of the study medication components;
• •Female participants who are pregnant, breastfeeding or who want to become pregnant;
• •COVID-19 symptoms;
• •Post COVID-19 syndrome with cardiovascular impairment;
• •Subjects who have participated in other study within the 12 months prior to screening (unless benefit is justified by the researcher).